Australia markets closed

Zentek Ltd. (ZEN.V)

TSXV - TSXV Real-time price. Currency in CAD
Add to watchlist
1.6000-0.0500 (-3.03%)
At close: 03:59PM EST

Zentek Ltd.

24 Corporate Court
Guelph, ON N1G 5G5
Canada
844-730-9822
https://www.zentek.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees29

Key executives

NameTitlePayExercisedYear born
Mr. Gregory Fenton C.F.A.CEO & Director325kN/AN/A
Ms. Wendy Ford CA, CPAChief Financial Officer250.53kN/AN/A
Dr. Francis Dube B.Sc.COO & Director300kN/AN/A
Dr. Colin van der Kuur B.Sc., DMINChief Science Officer74.89kN/AN/A
Mr. Ryan ShacklockSenior Vice President of Strategy & Business DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops graphene oxide synthesis and graphene synthesis. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada.

Corporate governance

Zentek Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.